1. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins

   • Iftekhar Mahmood
   • Martin D. Green

   Leading Article 30 September 2012 Pages: 331 - 347

   

2. Role of Cytochrome P450 Activity in the Fate of Anticancer Agents and in Drug Resistance

   • Bertrand Rochat

   Review Article 30 September 2012 Pages: 349 - 366

   

3. Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations

   • Vassilios I. Avramis
   • Eduard H. Panosyan

   Review Article 30 September 2012 Pages: 367 - 393

   

4. Pharmacokinetics of Famotidine in Infants

   • Larissa A. Wenning
   • M. Gail Murphy
   • Gregory L. Kearns

   Original Research Article 30 September 2012 Pages: 395 - 406

   

5. Topiramate Pharmacokinetics in Children and Adults with Epilepsy

   • Dina Battino
   • Danilo Croci
   • Emilio Perucca

   Original Research Article 30 September 2012 Pages: 407 - 416

   

6. Pharmacokinetic/Pharmacodynamic and Time-to-Event Models of Ribavirin-Induced Anaemia in Chronic Hepatitis C

   • Michel Tod
   • Muriel Farcy-Afif
   • Patrick Marcellin

   Original Research Article 30 September 2012 Pages: 417 - 428

   

7. Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring NuvaRing® with Oral Amoxicillin or Doxycycline in Two Randomised Trials

   • Peter Dogterom
   • Michiel W. van den Heuvel
   • Torben Thomsen

   Original Research Article 30 September 2012 Pages: 429 - 438

   

8. Practical Guidelines to Interpret Plasma Concentrations of Antiretroviral Drugs

   • Jonathan Leith
   • Ralf Hinzmann
   • Douglas Mayers

   Correspondence 30 September 2012 Pages: 439 - 439

9. The Authors’ Reply

   • Bregt S. Kappelhoff
   • Alwin D. R. Huitema
   • Jos H. Beijnen

   Correspondence 30 September 2012 Pages: 439 - 440